Skip to main content
Premium Trial:

Request an Annual Quote

Their Oligos Runneth Over

Premium

In an effort to soup up its oligonucleotide-producing Oligator technology, Illumina overshot its internal demand for the product and now plans to sell the surplus oligos to other companies. The original Oligator pumped out 768 oligos daily, and when cycle time was cut in half, output grew to two million oligos each year, says Jay Flatley, president and CEO.

The quest continues. “We’ll at least double that this year,” Flatley says, offering no specific target amount. “The rate at which we add capacity will be driven by outside demand.”

Illumina is negotiating with a few potential clients, but will not reveal names. “Most people aren’t going to want to disclose the fact that they’re buying lots of oligos,” Flatley says.

The company itself uses oligos to make arrays; it has four Oligators and “there are plans for more,” says spokesman William Craumer.

The oligo surfeit will also promote Illumina’s future SNP ventures. The company is poised to introduce a joint fiberoptic SNP genotyping effort with Applied Biosystems that is expected to process one thousand SNPs per minute, Craumer adds.

Key competitors in the oligo market are Operon, Sigma-Genosys, and Genset.

— Meredith Salisbury

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.